Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Isabelle VAN SEUNINGEN

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3131-2694; OpenAlex author ID A5010941913. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 6 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 18

  1. The kinase domain of TRPM7 interacts with PAK1 and regulates pancreatic cancer cell epithelial-to-mesenchymal transition. Co-author DOI 10.1038/s41419-025-07665-2↗
  2. A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms. Co-author DOI 10.1111/boc.202100003↗
  3. The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis. Last author DOI 10.3390/cancers13225746↗
  4. Antagonistic Roles of the Tumor Suppressor miR-210-3p and Oncomucin MUC4 Forming a Negative Feedback Loop in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers13246197↗
  5. Unsupervised Hierarchical Clustering of Pancreatic Adenocarcinoma Dataset from TCGA Defines a Mucin Expression Profile that Impacts Overall Survival. Last author DOI 10.3390/cancers12113309↗
  6. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype. Co-author DOI 10.1002/mc.23090↗
  7. Fine-tuning autophagy in pancreatic adenocarcinoma: full blockage is required. First author DOI 10.21037/atm.2019.03.01↗
  8. TGF-βRII Knock-down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Phosphorylation on S727. Co-author DOI 10.3390/cancers10080254↗
  9. The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting. Last author DOI 10.1016/j.critrevonc.2017.01.002↗
  10. The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling … Co-author DOI 10.1016/j.bbagrm.2015.10.014↗
  11. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Last author DOI 10.1016/j.bbamcr.2015.05.033↗
  12. The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways. Last author DOI 10.1016/j.bbrc.2014.12.025↗
  13. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. Last author DOI 10.1038/onc.2014.11↗
  14. Targeting MUC4 in pancreatic cancer: miRNAs. Last author DOI 10.18632/oncoscience.249↗
  15. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-re… Co-author DOI 10.18632/oncotarget.3414↗
  16. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Co-author DOI 10.1038/onc.2012.179↗
  17. The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. Last author DOI 10.1371/journal.pone.0032232↗
  18. Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Co-author DOI 10.1038/onc.2010.631↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nicolas Jonckheere · 16 shared papers, 2012–2025 · strength 1.50
  2. Fatima Lahdaoui · 6 shared papers, 2015–2021 · strength 0.50
  3. Romain Vasseur · 6 shared papers, 2015–2021 · strength 0.49
  4. Audrey Vincent · 6 shared papers, 2015–2022 · strength 0.46
  5. Nicolas Skrypek · 6 shared papers, 2012–2021 · strength 0.37
  6. Julie Auwercx · 2 shared papers, 2020–2025 · strength 0.32
  7. Mathieu Gautier · 2 shared papers, 2020–2025 · strength 0.32
  8. Nihad Boukrout · 3 shared papers, 2018–2021 · strength 0.32
  9. Jérôme Torrisani · 3 shared papers, 2015–2021 · strength 0.23
  10. Elsa Hadj Bachir · 2 shared papers, 2020–2022 · strength 0.22
  11. Nicolas Stoup · 2 shared papers, 2021–2022 · strength 0.22
  12. Stéphanie Truant · 2 shared papers, 2019–2022 · strength 0.20
  13. Pascal Pigny · 2 shared papers, 2011–2022 · strength 0.14
  14. Solange Tréhoux · 2 shared papers, 2015 · strength 0.12
  15. Charles Poiraud · 1 shared paper, 2022 · strength 0.12
  16. Yannick Delpu · 2 shared papers, 2015 · strength 0.10
  17. Mehdi El Amrani · 1 shared paper, 2019 · strength 0.08
  18. Vincent Drubay · 1 shared paper, 2018 · strength 0.08
  19. J Merlin · 2 shared papers, 2011–2012 · strength 0.06
  20. Mohamed Hebbar · 1 shared paper, 2013 · strength 0.04
  21. Ann Harris · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.